Smirnova OV, Sinyakov AA, Kasparov EV. Helicobacter pylori infection as a risk factor in the development of metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2025; 17(10): 110833 [PMID: 41179711 DOI: 10.4254/wjh.v17.i10.110833]
Corresponding Author of This Article
Olga V Smirnova, Professor, Laboratory of Clinical Pathophysiology, Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences”, Separate Subdivision Research Institute for Medical Problems of the North, Partizana Zheleznyaka Street 3G, Krasnoyarsk 660022, Russia. ovsmirnova71@mail.ru
Research Domain of This Article
Biochemical Research Methods
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Oct 27, 2025 (publication date) through Nov 16, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Smirnova OV, Sinyakov AA, Kasparov EV. Helicobacter pylori infection as a risk factor in the development of metabolic dysfunction-associated steatotic liver disease. World J Hepatol 2025; 17(10): 110833 [PMID: 41179711 DOI: 10.4254/wjh.v17.i10.110833]
World J Hepatol. Oct 27, 2025; 17(10): 110833 Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.110833
Helicobacter pylori infection as a risk factor in the development of metabolic dysfunction-associated steatotic liver disease
Olga V Smirnova, Aleksander A Sinyakov, Edward V Kasparov
Olga V Smirnova, Aleksander A Sinyakov, Edward V Kasparov, Laboratory of Clinical Pathophysiology, Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences”, Separate Subdivision Research Institute for Medical Problems of the North, Krasnoyarsk 660022, Russia
Author contributions: Smirnova OV wrote the original draft; Sinyakov AA contributed to conceptualization, writing, reviewing and editing; Smirnova OV, Sinyakov AA, and Kasparov EV participated in manuscript drafting. All the authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Olga V Smirnova, Professor, Laboratory of Clinical Pathophysiology, Federal Research Center “Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences”, Separate Subdivision Research Institute for Medical Problems of the North, Partizana Zheleznyaka Street 3G, Krasnoyarsk 660022, Russia. ovsmirnova71@mail.ru
Received: June 17, 2025 Revised: July 4, 2025 Accepted: August 28, 2025 Published online: October 27, 2025 Processing time: 133 Days and 5.3 Hours
Abstract
The problem of metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming a non-infectious pandemic, the growth drivers of which are obesity and diabetes mellitus. According to modern concepts, MASLD develops and progresses as a result of the interaction of multiple genetic, environmental and adaptive factors, which include specific genetic polymorphisms (for example, the patatin-like phospholipase domain-containing protein 3 gene) and epigenetic modifications, dietary patterns (for example, high consumption of saturated fats and fructose), physical inactivity, obesity, insulin resistance, dysregulation of adipokine production, lipotoxicity, oxidative stress, intestinal microbiota dysbiosis (small intestinal bacterial overgrowth syndrome). In addition, due to the high infection rate of Helicobacter pylori (up to 80%) of people in the population, the influence of this factor on the development and progression of MASLD cannot be ruled out. Ye et al presented a study investigating the relationship between Helicobacter pylori infection and metabolic dysfunction associated with hepatic steatosis and identified prognostic factors. Certainly, the work of the Chinese authors deserves attention and further study.
Core Tip: The editorial discusses risk factors (Helicobacter pylori infection, proinflammatory cytokines, adipokines, mitochondrial dysfunction, oxidative stress, insulin resistance, gut microbiota, and other indicators) in the development of metabolic dysfunction-associated steatotic liver disease. This issue is covered in an article by Ye et al, they show that in a large cross-sectional study involving 28624 adults, it was revealed that Helicobacter pylori infection is correlated with metabolic disturbances, particularly in obese and older individuals. This study is distinguished by its extremely promising and strategically new objective and a very impressive methodological level of research.
